Factory source Rosuvastatin - Rimegepant – CPF

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

"Control the standard by the details, show the power by quality". Our business has strived to establish a highly efficient and stable team staff and explored an effective good quality regulate course of action for Canagliflozin Metformin, Canagliflozin Nejm, Niraparib Manufacturer, With a wide range, top quality, reasonable rates and stylish designs, our products are extensively used with this industries and other industries.
Factory source Rosuvastatin - Rimegepant – CPF Detail:

Rimegepant is a small molecule inhibitor of the calcitonin gene-related peptide (CGRP) receptor that blocks the action of CGRP, a potent vasodilator believed to play a role in migraine headaches. Rimegepant is approved for treatment of acute migraine attacks. In clinical trials, rimegepant was generally well tolerated with only rare instances of transient serum aminotransferase elevations during therapy and with no reported instances of clinically apparent liver injury.

Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache. While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g. [erenumab], [fremanezumab], [galcanezumab]), rimegepant and [ubrogepant] are the only members of the “gepants” family of medications remaining in development, and the only CGRP antagonists that possess oral bioavailability. The current standard of migraine therapy involves abortive treatment with “triptans”, such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular and cardiovascular disease due to their vasoconstrictive properties. Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore safer for use in patients with contraindications to standard therapy.

Rimegepant is a Calcitonin Gene-related Peptide Receptor Antagonist. The mechanism of action of rimegepant is as a Calcitonin Gene-related Peptide Receptor Antagonist.

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

OUR STRENGTH

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect. 

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.


VIEW MORE


VIEW MORE

International cooperation
International cooperation
Domestic cooperation
Domestic cooperation


Product detail pictures:

Factory source Rosuvastatin - Rimegepant  – CPF detail pictures


Related Product Guide:

Our eternal pursuits are the attitude of "regard the market, regard the custom, regard the science" and the theory of "quality the basic, belief the very first and management the advanced" for Factory source Rosuvastatin - Rimegepant – CPF , The product will supply to all over the world, such as: Ireland, Boston, Lithuania, Our company always concentrate on the development of the international market. We have a lot of customers in Russia , European countries, the USA, the Middle East countries and Africa countries. We always follow that quality is foundation while service is guarantee to meet all customers.
  • We have been appreciated the Chinese manufacturing, this time also did not let us disappoint,good job!
    5 Stars By Mavis from kazakhstan - 2018.12.14 15:26
    The customer service staff is very patient and has a positive and progressive attitude to our interest, so that we can have a comprehensive understanding of the product and finally we reached an agreement, thanks!
    5 Stars By Prima from Bhutan - 2017.06.29 18:55
    Write your message here and send it to us